<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7362854\results\search\country\results.xml">
  <result pre="Fortunately, after analyzing the complete genome of SARS-CoV-2 from Wuhan," exact="China" post="[13,14], important structural and biochemical details are now available"/>
  <result pre="of RNA or DNA. This antiviral drug was developed in" exact="Japan" post="and approved in 2014 for treating viral strains unresponsive"/>
  <result pre="III clinical trials as a possible treatment for COVID-19 in" exact="the USA" post="(remdesivir) and Japan (favipiravir). Ruxolitinib (10), an anticancer drug"/>
  <result pre="a possible treatment for COVID-19 in the USA (remdesivir) and" exact="Japan" post="(favipiravir). Ruxolitinib (10), an anticancer drug tested for its"/>
  <result pre="inefficient according to the first randomized trial (158 patients) in" exact="China" post="on patients with severe COVID-19 symptoms [130]. In addition,"/>
  <result pre="Res.1002201344645424084488 55FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymeraseProc." exact="Japan" post="Acad., Series B9372017449463 56PiscianzE.CuzzoniE.SharmaR.TesserA.SapraP.TommasiniA.Reappraisal of antimalarials in interferonopathies: new"/>
  <result pre="an open-label control studyEngineering202010.1016/j.eng.2020.03.007 135EkinsS.LaneT.R.MadridP.B.Tilorone: a broad-spectrum antiviral invented in" exact="the USA" post="and commercialized in Russia and beyondPharm. Res. (N. Y.)3720207110.1007/s11095-020-02799-8"/>
  <result pre="a broad-spectrum antiviral invented in the USA and commercialized in" exact="Russia" post="and beyondPharm. Res. (N. Y.)3720207110.1007/s11095-020-02799-8 136SaxenaA.Drug targets for COVID-19"/>
 </snippets>
</snippetsTree>
